Latest Period
Q1 2026
Security Snapshot
Vanda Pharmaceuticals Inc. - COMMON STOCK (VNDA) Institutional Ownership
CUSIP: 921659108
13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026
Institutions Reporting
168
Shares (Excl. Options)
46,213,173
Price
$6.91
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / COMMON STOCK
- Symbol
- VNDA on Nasdaq
- Shares outstanding
- 59,128,667
- Price per share
- $6.91
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 46,213,173
- Total reported value
- $319,343,717
- % of total 13F portfolios
- 0%
- Share change
- +4,197,967
- Value change
- +$24,964,546
- Number of holders
- 168
- Price from insider filings
- $6.91
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- VNDA - Vanda Pharmaceuticals Inc. - COMMON STOCK is tracked under CUSIP 921659108.
- 168 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 152 to 168 between Q4 2025 and Q1 2026.
- Reported value moved from $369,630,068 to $319,343,717.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 168 institutions filings for Q1 2026.
Security key
921659108
Latest holder period
Q1 2026
13F holders
168
13D/G owners
4
CIK / CUSIP context first
Open Q1 2026 holders
VNDA full holder history
Vanda Pharmaceuticals Inc. SEC filings
Vanda Pharmaceuticals Inc. company facts
Vanda Pharmaceuticals Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 921659108:
Significant Owners of Vanda Pharmaceuticals Inc. - COMMON STOCK (VNDA) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 8.1% | -47% | $20,206,904 | -$18,941,173 | 4,699,280 | -48% | BlackRock, Inc. | 31 Jan 2025 |
| STATE STREET CORP | 5.1% | $20,837,533 | 3,015,562 | STATE STREET CORPORATION | 31 Mar 2026 | |||
| BlackRock Portfolio Management LLC | 4.2% | -22% | $17,333,652 | -$5,134,648 | 2,508,488 | -23% | BlackRock Portfolio Management LLC | 31 Mar 2026 |
| MILLENNIUM MANAGEMENT LLC | 2.8% | -50% | $14,808,391 | -$12,712,063 | 1,679,013 | -46% | Millennium Management LLC | 31 Dec 2025 |
As of 31 Mar 2026, 168 institutional investors reported holding 46,213,173 shares of Vanda Pharmaceuticals Inc. - COMMON STOCK (VNDA). This represents 78% of the company’s total 59,128,667 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Vanda Pharmaceuticals Inc. - COMMON STOCK (VNDA) together control 65% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 12% | 7,275,988 | -6.4% | 0% | $50,277,078 |
| RENAISSANCE TECHNOLOGIES LLC | 6.4% | 3,759,559 | +11% | 0.04% | $25,978,553 |
| STATE STREET CORP | 5.1% | 3,015,562 | +139% | 0% | $20,837,533 |
| AIGH Capital Management LLC | 4.7% | 2,750,000 | +38% | 3.9% | $19,002,500 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.2% | 2,481,491 | 0% | 0% | $17,147,103 |
| MILLENNIUM MANAGEMENT LLC | 3.2% | 1,881,001 | +12% | 0.01% | $12,997,717 |
| ACADIAN ASSET MANAGEMENT LLC | 3% | 1,795,592 | -26% | 0.02% | $12,403,000 |
| DIMENSIONAL FUND ADVISORS LP | 3% | 1,771,593 | -16% | 0% | $12,239,985 |
| AQR CAPITAL MANAGEMENT LLC | 2.7% | 1,603,576 | +156% | 0.01% | $11,080,710 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4% | 1,442,965 | +3.7% | 0% | $9,973,228 |
| TWO SIGMA INVESTMENTS, LP | 2.4% | 1,398,201 | +43% | 0.01% | $9,661,569 |
| Krensavage Asset Management, LLC | 2% | 1,180,388 | 0% | 3.2% | $8,156,000 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 2% | 1,168,681 | +65% | 0.03% | $8,075,586 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.7% | 1,014,522 | 0% | 0% | $7,010,347 |
| Empire Financial Management Company, LLC | 1.6% | 922,245 | -17% | 1.4% | $6,372,712 |
| GOLDMAN SACHS GROUP INC | 1.4% | 838,233 | +105% | 0% | $5,792,190 |
| CITADEL ADVISORS LLC | 1.1% | 633,354 | 0% | $4,376,476 | |
| MARSHALL WACE, LLP | 1% | 596,002 | 0% | $4,118,375 | |
| FEDERATED HERMES, INC. | 0.97% | 575,389 | +3.8% | 0.01% | $3,975,938 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.93% | 551,770 | +10% | 0% | $3,812,731 |
| NORTHERN TRUST CORP | 0.76% | 450,981 | +5.1% | 0% | $3,116,278 |
| MORGAN STANLEY | 0.75% | 440,794 | -26% | 0% | $3,045,887 |
| VANGUARD FIDUCIARY TRUST CO | 0.66% | 387,964 | 0% | 0% | $2,680,831 |
| Connor, Clark & Lunn Investment Management Ltd. | 0.64% | 376,858 | -49% | 0.01% | $2,604,089 |
| Quantinno Capital Management LP | 0.55% | 327,193 | +25% | 0% | $2,260,904 |
Institutional Holders of Vanda Pharmaceuticals Inc. - COMMON STOCK (VNDA) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 46,213,173 | $319,343,717 | +$24,964,546 | $6.91 | 168 |
| 2025 Q4 | 41,919,124 | $369,630,068 | -$8,977,057 | $8.82 | 152 |
| 2025 Q3 | 44,885,173 | $223,975,088 | -$615,405 | $4.99 | 146 |
| 2025 Q2 | 45,005,222 | $212,432,729 | +$5,358,364 | $4.72 | 137 |
| 2025 Q1 | 43,925,314 | $201,682,351 | +$2,283,938 | $4.59 | 145 |
| 2024 Q4 | 43,147,771 | $206,663,421 | -$5,834,005 | $4.79 | 146 |
| 2024 Q3 | 43,981,766 | $206,261,308 | +$385,141 | $4.69 | 151 |
| 2024 Q2 | 43,532,710 | $245,988,772 | -$20,221,284 | $5.65 | 147 |
| 2024 Q1 | 48,062,202 | $197,420,430 | -$11,386,730 | $4.11 | 140 |
| 2023 Q4 | 50,696,953 | $213,770,549 | -$8,165,025 | $4.22 | 154 |
| 2023 Q3 | 52,588,884 | $227,183,918 | -$23,037,768 | $4.32 | 179 |
| 2023 Q2 | 56,248,075 | $370,694,666 | -$14,253,028 | $6.59 | 187 |
| 2023 Q1 | 58,308,583 | $395,914,559 | +$17,232,279 | $6.79 | 176 |
| 2022 Q4 | 55,589,814 | $410,808,616 | +$2,189,163 | $7.39 | 186 |
| 2022 Q3 | 55,141,714 | $544,810,424 | -$11,288,828 | $9.88 | 171 |
| 2022 Q2 | 56,006,392 | $610,516,173 | -$187,164 | $10.90 | 166 |
| 2022 Q1 | 56,272,506 | $636,565,420 | +$17,401,270 | $11.31 | 181 |
| 2021 Q4 | 54,252,447 | $851,181,026 | -$29,760,480 | $15.69 | 192 |
| 2021 Q3 | 55,224,691 | $946,649,896 | +$4,381,069 | $17.14 | 173 |
| 2021 Q2 | 54,791,110 | $1,178,013,080 | +$10,402,309 | $21.51 | 176 |
| 2021 Q1 | 54,541,422 | $819,510,471 | -$4,488,836 | $15.02 | 182 |
| 2020 Q4 | 55,039,795 | $723,395,120 | +$5,524,875 | $13.14 | 170 |
| 2020 Q3 | 54,414,204 | $525,712,121 | -$8,605,614 | $9.66 | 159 |
| 2020 Q2 | 55,140,491 | $630,777,920 | +$15,624,266 | $11.44 | 159 |
| 2020 Q1 | 53,776,502 | $557,290,753 | +$129,584 | $10.36 | 154 |
| 2019 Q4 | 52,825,174 | $866,806,457 | -$1,382,881 | $16.41 | 170 |
| 2019 Q3 | 52,964,599 | $703,437,080 | -$21,562,526 | $13.28 | 161 |
| 2019 Q2 | 54,287,178 | $764,978,865 | +$13,754,283 | $14.09 | 158 |
| 2019 Q1 | 54,377,164 | $1,000,565,489 | +$5,340,845 | $18.40 | 175 |
| 2018 Q4 | 53,011,338 | $1,384,693,451 | +$27,801,917 | $26.13 | 180 |
| 2018 Q3 | 52,207,975 | $1,198,127,037 | +$80,020,008 | $22.95 | 157 |
| 2018 Q2 | 49,022,523 | $933,879,055 | +$18,597,031 | $19.05 | 134 |
| 2018 Q1 | 48,202,587 | $812,206,007 | +$128,627,396 | $16.85 | 130 |
| 2017 Q4 | 40,872,797 | $621,278,889 | +$12,023,355 | $15.20 | 125 |
| 2017 Q3 | 39,724,724 | $711,076,419 | +$17,158,833 | $17.90 | 137 |
| 2017 Q2 | 38,857,064 | $633,364,808 | -$6,543,528 | $16.30 | 131 |
| 2017 Q1 | 39,704,878 | $555,846,956 | +$44,096,425 | $14.00 | 134 |
| 2016 Q4 | 40,641,934 | $648,300,745 | -$10,229,525 | $15.95 | 141 |
| 2016 Q3 | 40,758,505 | $678,216,752 | +$66,622,806 | $16.64 | 137 |
| 2016 Q2 | 37,247,837 | $416,814,941 | -$42,220,720 | $11.19 | 115 |
| 2016 Q1 | 41,259,486 | $344,882,956 | -$12,846,699 | $8.36 | 115 |
| 2015 Q4 | 42,551,919 | $396,337,229 | -$31,495,959 | $9.31 | 116 |
| 2015 Q3 | 42,714,610 | $481,809,118 | +$465,619 | $11.28 | 121 |
| 2015 Q2 | 42,413,548 | $538,068,965 | -$35,411,925 | $12.69 | 109 |
| 2015 Q1 | 46,293,079 | $430,514,637 | -$27,508,593 | $9.30 | 108 |
| 2014 Q4 | 47,666,210 | $682,064,306 | +$77,111,645 | $14.32 | 108 |
| 2014 Q3 | 41,299,517 | $428,691,693 | +$24,205,345 | $10.38 | 101 |
| 2014 Q2 | 38,482,247 | $622,313,434 | +$52,888,872 | $16.18 | 110 |
| 2014 Q1 | 35,159,995 | $571,479,438 | +$57,348,441 | $16.25 | 109 |